Gilead (GILD) At Key Q4 Support Into Earnings (GMR Macro Technicals, 24 Oct 2018)
Gilead (GILD) is at key Nov/Q4 support ahead of earnings. Action below there should sharply extend the decline. The focal point in S&P remains the 2740 Quarterly trend (as similar Q4 trends are in place in NDX and INDU). US Treasuries remain trend down, with bonds at greatest risk. See GMR Macro Technicals for specific price levels and detailed Trade Strategy.Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. The company's primary areas of focus include viral diseases, inflammatory and fibrotic diseases and oncology. The company's products include: Biktarvy for the treatment of HIV-1 infection in certain patients; Vosevi?, a single tablet regimen of sofosbuvir, velpatasvir and voxilaprevir for the re-treatment of chronic hepatitis C virus infection in adults; Vemlidy? for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; and Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
Global Market Research provide quantitative, algorithm-based research to institutional investors in the Equity, FX, Rate, Commodity and Blockchain markets. GMR provide significant value to our wide range of clients in four distinct ways:
- Translate broad Macro ideas into actionable Price Strategy;
- Apply the GMR proprietary method as an independent filter for client-driven ideas;
- Utilize GMR's unique algorithm to identify markets with potential for major price shock;
- Bespoke Analysis.
GMR regularly publish four specialized subscription reports: MACRO Technicals® focuses on the major USD crosses, US Treasury yields and Equity markets. GMR Weekly Notes® identifies a Top 10 list of risk/reward opportunities across asset classes. Petro-Technicals® covers Crude Oil and Natural Gas markets; Bitcoin Technicals® focuses on blockchain technology.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.